Suresh Narva

Suresh Narva

Auto-generated profile, based on publicly available information

Suresh Narva

Department of Chemistry

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SNSuresh Narva
Suresh Narva
SCSurendar Chitti
Surendar Chitti
BBBhaskara Rao Bala
Bhaskara Rao Bala
MAmallika Alvala
mallika Alvala
NJNishant Jain
Nishant Jain
KSKondapalli Venkata Gowri Chandra Sekhar
Kondapalli Venkata Gowri Chandra Sekhar

6 May 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LSLi-Wen Shen
Li-Wen Shen
MQMan-Qing Qian
Man-Qing Qian
KYKai Yu
Kai Yu
SNSuresh Narva
Suresh Narva
FYFei Yu
Fei Yu
WZWen Zhang
Wen Zhang
Proteolytic cleavage of influenza A virus (IAV) hemagglutinin by host proteases is crucial for virus infectivity and spread. The transmembrane serine protease TMPRSS2 was previously identified as the essential protease that can cleave hemagglutinin of many subtypes of influenza virus and spike protein of coronavirus. Herein, we found that a guanine rich tract, capable of forming intramolecular G-quadruplex in the presence of potassium ions, in the promoter region of human TMPRSS2 gene was quite important for gene transcriptional activity, hence affecting its function. Furthermore, 7 new synthesized benzoselenoxanthene analogues were found to enable stabilizing such G-quadruplex. More importantly, compounds can down-regulate TMPRSS2 gene expression, especially endogenous TMPRSS2 protein levels, and consequently suppress influenza A virus propagation in vitro. Our results provide a new strategy for anti-influenza A virus infection by small molecules targeting the TMPRSS2 gene G-quadruplex and thus inhibiting TMPRSS2 expression, which is valuable for developing small molecule drugs against influenza A virus and also may be a potential candidate as anti- SARS-CoV-2 (Severe Acute Respiratory Syndrome CoV 2) lead molecules.

29 November 2019 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JLJia-Chun Liu
Jia-Chun Liu
SNSuresh Narva
Suresh Narva
KZKang Zhou
Kang Zhou
WZWen Zhang
Wen Zhang
At present, cancers have been causing deadly fears to humans and previously unpredictable losses to health. Especially, lung cancer is one of the most common causes of cancer-related mortality accounting for approximately 15% of all cancer cases worldwide. While Non-Small Cell Lung Carcinomas (NSCLCs) makes up to 80% of lung cancer cases. The patient compliance has been weakening because of serious drug resistance and adverse drug effects. Therefore, there is an urgent need for the development of novel structural agents to inhibit NSCLCs. Nitrogen-containing heterocyclic compounds exhibit wide range of biological properties, especially antitumor activity. We reviewed some deadly defects of clinical medicines for the lung cancer therapy and importance of nitrogen based heterocyclic derivatives against NSCLCs. Nitrogen heterocycles exhibit significant antitumor activity against NSCLCs. Nitrogen heterocyclic hybrids could be developed as multi-target-directed NSCLC inhibitors and it is believed that the review is significant for rational designs and new ideas in the development of nitrogen heterocyclic-based drugs.

1 September 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KZKang Zhou
Kang Zhou
JLJiachun Liu
Jiachun Liu
XXXuqiong Xiong
Xuqiong Xiong
MCMei Cheng
Mei Cheng
XHXiaolin Hu
Xiaolin Hu
WZWen Zhang
Wen Zhang

1 August 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SNSuresh Narva
Suresh Narva
SCSurendar Chitti
Surendar Chitti
SASuresh Amaroju
Suresh Amaroju
DBDebanjan Bhattacharjee
Debanjan Bhattacharjee
BRBala Bhaskara Rao
Bala Bhaskara Rao
KSKondapalli Venkata Gowri Chandra Sekhar
Kondapalli Venkata Gowri Chandra Sekhar

14 August 2020 in ACS Omega
Verified
Journal Article
Closed access
SNSuresh Narva
Suresh Narva
XXXuqiong Xiong
Xuqiong Xiong
XMXudong Ma
Xudong Ma
Yoshimasa TanakaYoshimasa Tanaka
Yoshimasa Tanaka
YWYanling Wu
Yanling Wu
WZWen Zhang
Wen Zhang